Global Breast Cancer Detection Market Size Likely to Surpass at a CAGR of 10.3% By 2033

As per the current market research conducted by the CMI Team, the global Breast Cancer Detection Market size is expected to record a CAGR of 10.3% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 27.1 Billion. By 2033, the valuation is anticipated to reach USD 93.6 Billion.

Breast Cancer Detection Market: Growth Factors and Dynamics

• Technological Advancements: Ongoing innovations in breast cancer detection technologies, such as digital mammography and MRI, drive higher sensitivity and accuracy, thereby encouraging early diagnosis and treatment.

• Awareness Campaigns: Public health efforts and advocacy campaigns educate women about the importance of regular breast cancer screening, fostering a proactive approach to healthcare and driving market growth.

• Aging Population: The aging demographic, particularly in developed regions, fuels demand screening and diagnostic services as older individuals face a higher risk of developing breast cancer.

• Personalized Medicine: Advancements in genomic testing and molecular diagnostics enable personalized treatment approaches, spurring demand for tailored screening and diagnostic solutions.

• Competitive Landscape: Intense competition among market players stimulates innovation, product development, and market expansion efforts.

• Regulatory Environment: Stringent regulatory standards and approval processes influence product development timelines and market entry strategies.

• Healthcare Infrastructure: Disparities in healthcare infrastructure and access to screening services impact market dynamics, particularly in underserved regions.

• Economic Factors: Affordability concerns and reimbursement policies affect patient access to screening and diagnostic services, influencing market demand and adoption rates.

• Emerging Markets: Growing healthcare expenditure, increasing awareness, and expanding access to healthcare in emerging economies present significant growth opportunities for breast cancer detection market players.

Breast Cancer Detection Market: Partnership and Acquisitions

• In November 2022, Koninklijke Philips N.V. unveiled a next-generation compact portable ultrasound solution during the Radiological Society of North America (RSNA) annual meeting, aiming to extend premium cart-based ultrasound system diagnostics to a broader patient base. The portable device offers versatility and high-quality imaging, compatible with Philips ultrasound systems Affiniti and EPIQ transducers. This move bolsters the company’s product portfolio expansion efforts.

• In November 2022, Siemens Healthineers and Atrium Health, a renowned non-profit healthcare provider acclaimed for its leading pediatric, cancer, and cardiac care programs, announced a multi-year value partnership. Focused on enhancing care accessibility in Atrium Health’s southeastern United States service area, the strategic collaboration aims to promote health equity and bolster economic mobility. Atrium Health is investing over $140 million in Siemens Healthineers’ equipment and devices, encompassing advanced imaging technology, radiation oncology, and precision endovascular robotics, propelling the company’s business expansion initiatives.

Report Scope

Breast Cancer Detection Market: COVID-19 Analysis

The COVID-19 pandemic has significantly impacted the breast cancer detection market, leading to both challenges and opportunities:

• Disruption in Screening Programs: The COVID-19 pandemic has disrupted routine breast cancer screening programs worldwide. Many healthcare facilities postponed non-urgent appointments and screenings to prioritize COVID-19 care and reduce the risk of virus transmission. As a result, the number of mammograms and other screening tests performed during the pandemic significantly decreased, leading to a potential backlog of undiagnosed cases.

• Delayed Diagnoses: The decrease in screening rates during the pandemic has raised concerns about delayed breast cancer diagnoses. Early detection is crucial for successful treatment and improved outcomes in breast cancer patients. Delayed diagnoses may result in cancers being detected at later stages when they are more challenging to treat and may have already spread to other parts of the body.

• Strain on Healthcare Systems: The surge in COVID-19 cases has strained healthcare systems globally, with hospitals and healthcare facilities overwhelmed by the influx of patients requiring intensive care and respiratory support. The diversion of resources, including staff, equipment, and hospital beds, to COVID-19 care has impacted the capacity of healthcare systems to deliver timely breast cancer screening and diagnostic services.

• Adoption of Telemedicine: The COVID-19 pandemic has accelerated the adoption of telemedicine and virtual healthcare services. Healthcare providers have leveraged telemedicine platforms to conduct remote consultations, follow-ups, and counselling sessions with breast cancer patients. Telemedicine offers a safe and convenient alternative to in-person visits, ensuring continuity of care and reducing the risk of exposure to the virus.

• Emphasis on Early Detection: Despite the challenges posed by the pandemic, the importance of early detection of breast cancer remains paramount. Healthcare organizations, advocacy groups, and healthcare professionals have intensified efforts to raise awareness about breast cancer symptoms, risk factors, and the importance of self-examinations at home. Educational campaigns have encouraged women to remain vigilant about their breast health and seek medical attention if they notice any concerning changes or symptoms.

• Innovation in Screening Technologies: The COVID-19 pandemic has prompted innovation in remote monitoring devices, digital health solutions, and artificial intelligence (AI) technologies for breast cancer detection. Researchers and developers are exploring new approaches to breast cancer screening, such as at-home screening kits, wearable devices for continuous monitoring of breast health, and AI-powered risk assessment tools that analyze imaging data for early signs of cancer. These advancements have the potential to revolutionize breast cancer detection by making screening more accessible, convenient, and accurate.

• Resilience and Adaptability: The COVID-19 pandemic has underscored the importance of resilience and adaptability in healthcare systems and breast cancer detection strategies. Healthcare providers have demonstrated remarkable resilience in adapting to rapidly changing circumstances, implementing new protocols, and finding innovative solutions to continue providing essential care to patients. The pandemic has highlighted the need for flexible and adaptable screening programs that can quickly adjust to disruptions and prioritize patient safety while maintaining high standards of care.

Overall, while the COVID-19 pandemic has presented significant challenges to the breast cancer detection market, it has also catalyzed innovation, resilience, and adaptability. By leveraging telemedicine, emphasizing early detection, and advancing screening technologies, healthcare stakeholders can mitigate the impact of the pandemic on breast cancer diagnosis and treatment, ultimately improving outcomes for patients.

List of the prominent players in the Breast Cancer Detection Market:

• Hologic Inc.
• GE Healthcare (a division of General Electric Company)
• Siemens Healthineers AG
• Koninklijke Philips N.V.
• Fujifilm Holdings Corporation
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Agilent Technologies Inc.
• Roche Diagnostics (a division of F. Hoffmann-La Roche Ltd)
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• Myriad Genetics Inc.
• Becton, Dickinson and Company (BD)
• Genomic Health Inc. (now part of Exact Sciences)
• PerkinElmer Inc.
• Others

The Breast Cancer Detection Market is segmented as follows:

By Technology

• Traditional imaging
• Advanced imaging
• AI-powered diagnostics
• Liquid biopsy

By Application

• Screening
• Diagnosis
• Prognosis

By End-Use

• Hospitals & Clinics
• Diagnostic imaging centers
• Breast care centers
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America